Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (142058) 142058
Newsletter (27496) 27496
Book Review (21030) 21030
Newspaper Article (17490) 17490
Publication (9753) 9753
Conference Proceeding (1017) 1017
Trade Publication Article (997) 997
Book Chapter (898) 898
Magazine Article (825) 825
Web Resource (366) 366
Dissertation (347) 347
Transcript (227) 227
Book / eBook (175) 175
Government Document (48) 48
Report (42) 42
Reference (36) 36
Paper (21) 21
Data Set (15) 15
Journal / eJournal (10) 10
Streaming Video (4) 4
Poster (3) 3
Presentation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (101948) 101948
humans (95909) 95909
male (53888) 53888
hepatitis (53761) 53761
female (52095) 52095
adult (41057) 41057
middle aged (40901) 40901
hepatitis c virus (36700) 36700
hepatitis c (36404) 36404
gastroenterology & hepatology (32349) 32349
health aspects (25623) 25623
research (22927) 22927
hepatitis b (22589) 22589
interferon (21755) 21755
aged (21214) 21214
liver (21066) 21066
infection (20861) 20861
medical research (16819) 16819
antiviral agents - therapeutic use (15639) 15639
risk factors (15601) 15601
hepatitis b virus (14908) 14908
infections (14870) 14870
liver diseases (14836) 14836
care and treatment (14726) 14726
medicine, experimental (13984) 13984
virology (13801) 13801
infectious diseases (13665) 13665
analysis (13290) 13290
animals (13193) 13193
immunology (11885) 11885
liver cirrhosis (11743) 11743
adolescent (11732) 11732
hepatitis c, chronic - drug therapy (11686) 11686
virus diseases (11082) 11082
cirrhosis (11078) 11078
prevalence (11027) 11027
genotype (10845) 10845
treatment outcome (10816) 10816
abridged index medicus (10419) 10419
hepacivirus - genetics (10368) 10368
disease (10139) 10139
liver cancer (10119) 10119
viruses (10023) 10023
antiviral agents (9939) 9939
therapy (9385) 9385
virus-infection (9273) 9273
hepatocellular-carcinoma (8898) 8898
hepatocellular carcinoma (8747) 8747
biological response modifiers (8662) 8662
drug therapy (8575) 8575
patients (8566) 8566
genetic aspects (8555) 8555
liver - pathology (8282) 8282
cancer (8203) 8203
ribavirin (8137) 8137
interferon-alpha - therapeutic use (8032) 8032
fibrosis (7996) 7996
medicine, general & internal (7697) 7697
retrospective studies (7620) 7620
young adult (7594) 7594
diagnosis (7510) 7510
gastroenterology and hepatology (7369) 7369
epidemiology (7346) 7346
communicable diseases (7194) 7194
drug therapy, combination (7124) 7124
hepatitis c, chronic - complications (7084) 7084
hiv (7002) 7002
chronic disease (6995) 6995
chronic hepatitis-c (6976) 6976
transplantation (6951) 6951
oncology (6834) 6834
hepatitis b virus - genetics (6811) 6811
medicine (6689) 6689
biopsy (6647) 6647
hepatology (6596) 6596
pharmacology & pharmacy (6534) 6534
child (6505) 6505
prognosis (6500) 6500
hcv (6415) 6415
mortality (6293) 6293
pharmaceutical industry (6262) 6262
digestive system diseases (6224) 6224
studies (6037) 6037
mice (5991) 5991
proteins (5931) 5931
surgery (5814) 5814
hepatitis c - complications (5784) 5784
human immunodeficiency virus--hiv (5777) 5777
development and progression (5723) 5723
rna (5684) 5684
expression (5642) 5642
research article (5596) 5596
hepatitis-c virus (5566) 5566
microbiology (5504) 5504
ribavirin - therapeutic use (5503) 5503
medicine & public health (5480) 5480
viral load (5470) 5470
antigens (5459) 5459
time factors (5407) 5407
risk (5403) 5403
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (90) 90
Online Resources - Online (40) 40
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Scarborough Hospital - Online (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Mt Sinai Hospital - Pathology (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
UTL at Downsview - May be requested (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (180386) 180386
French (2122) 2122
Spanish (1571) 1571
German (1349) 1349
Japanese (1090) 1090
Chinese (906) 906
Korean (872) 872
Russian (710) 710
Italian (400) 400
Portuguese (372) 372
Polish (343) 343
Turkish (211) 211
Hungarian (164) 164
Romanian (114) 114
Czech (101) 101
Croatian (89) 89
Serbian (41) 41
Dutch (38) 38
Danish (32) 32
Swedish (27) 27
Persian (26) 26
Norwegian (19) 19
Slovak (18) 18
Hebrew (13) 13
Ukrainian (9) 9
Bosnian (7) 7
Slovenian (6) 6
Urdu (6) 6
Finnish (5) 5
Bulgarian (4) 4
Icelandic (3) 3
Lithuanian (3) 3
Belarusian (2) 2
Catalan (2) 2
Albanian (1) 1
Azerbaijani (1) 1
Hindi (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chronic Hepatitis C Infection
by Rosen, Hugo R
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2429 - 2438
This article reviews the evaluation and initial management of chronic hepatitis C infection, with particular attention to the use of new directly acting... 
UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | ANTIVIRAL THERAPY | PEGINTERFERON ALPHA-2B | COMBINATION THERAPY | GENOTYPE 1 INFECTION | FIBROSIS PROGRESSION | NATURAL-HISTORY | VIROLOGICAL RESPONSE | VIRAL CLEARANCE | Case studies | Antiviral agents | Care and treatment | Usage | Genetic aspects | Diagnosis | Hepatitis C | Health aspects | Substance abuse treatment | Transplants & implants | Chronic infection | Cytotoxicity | Infections | Patients | Liver cancer | Genotype & phenotype | Hepatitis | Lymphocytes | Human immunodeficiency virus--HIV | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Chronic hepatitis C
: current disease management
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
2000, NIH publication, Volume no. 00-4230
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | Hepatitis C virus
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Chronic hepatitis C
: current disease management
and National Digestive Diseases Information Clearinghouse (U.S.)National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
2003, NIH publication, Volume no. 03-4230
Hepatitis C virus
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Chronic hepatitis C virus
: advances in treatment, promise for the future
by Shiffman, Mitchell L
2012, ISBN 9781461411925
pathogenicity | Liver Transplantation | therapy | Antiviral Agents | Hepacivirus | therapeutic use | Hepatitis C, Chronic
Web Resource
Details down arrow
5. Full Text Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
by Lawitz, Eric and Mangia, Alessandra and Wyles, David and Rodriguez-Torres, Maribel and Hassanein, Tarek and Gordon, Stuart C and Schultz, Michael and Davis, Mitchell N and Kayali, Zeid and Reddy, K. Rajender and Jacobson, Ira M and Kowdley, Kris V and Nyberg, Lisa and Subramanian, G. Mani and Hyland, Robert H and Arterburn, Sarah and Jiang, Deyuan and McNally, John and Brainard, Diana and Symonds, William T and McHutchison, John G and Sheikh, Aasim M and Younossi, Zobair and Gane, Edward J
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
In two studies of sofosbuvir for previously untreated HCV infection, patients with genotype 1, 4, 5, or 6 had a 90% rate of sustained virologic response in a... 
ALPHA-2A | MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | VIRUS-INFECTION | POLYMERASE | UPDATE | PREVALENCE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Young Adult | Adult | Female | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Logistic Models | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Sofosbuvir | Antiviral agents | Complications and side effects | Causes of | Dosage and administration | Research | Hepatitis C virus | Blood diseases | Headache | Clinical trials | Chronic infection | Fatigue | Nausea | Ribavirin | Studies | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Drug dosages | Genotypes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
by Roth, David, Dr and Nelson, David R, MD and Bruchfeld, Annette, MD and Liapakis, AnnMarie, MD and Silva, Marcelo, MD and Monsour, Howard, MD and Martin, Paul, MD and Pol, Stanislas, MD and Londoño, Maria-Carlota, MD and Hassanein, Tarek, MD and Zamor, Philippe J, MD and Zuckerman, Eli, MD and Wan, Shuyan, PhD and Jackson, Beth, MLAS and Nguyen, Bach-Yen, MD and Robertson, Michael, MD and Barr, Eliav, MD and Wahl, Janice, MD and Greaves, Wayne, MD
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10003, pp. 1537 - 1545
Summary Background Chronic hepatitis C virus (HCV) infection in patients with stage 4–5 chronic kidney disease increases the risk of death and renal graft... 
Internal Medicine | TRANSIENT ELASTOGRAPHY | MEDICINE, GENERAL & INTERNAL | DIALYSIS PATIENTS | CIRRHOSIS | LIVER FIBROSIS | MK-5172 | RANDOMIZED-TRIAL | RENAL-DISEASE | HCV | RIBAVIRIN | TRANSPLANTATION | Benzofurans - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Male | Treatment Outcome | Hepatitis C, Chronic - complications | Renal Insufficiency, Chronic - complications | Hepatitis C, Chronic - drug therapy | Renal Insufficiency, Chronic - drug therapy | RNA, Viral | Female | Aged | Imidazoles - therapeutic use | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Quinoxalines - therapeutic use | Hypertension | Medical research | Surfers | Care and treatment | Chronic kidney failure | Gastrointestinal diseases | Liver | Medicine, Experimental | Genetic aspects | Hepatitis C virus | Health aspects | Analysis | Hepatitis | Interferon | Kidney diseases | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
by Jacobson, Ira M and McHutchison, John G and Dusheiko, Geoffrey and Di Bisceglie, Adrian M and Reddy, K. Rajender and Bzowej, Natalie H and Marcellin, Patrick and Muir, Andrew J and Ferenci, Peter and Flisiak, Robert and George, Jacob and George, Shelley and Rizzetto, Mario and Shouval, Daniel and Sola, Ricard and Terg, Ruben A and Yoshida, Eric M and Adda, Nathalie and Bengtsson, Leif and Sankoh, Abdul J and Kieffer, Tara L and Kauffman, Robert S and M.D, Stefan Zeuzem and ADVANCE Study Team
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Viral Hepatitis: Chronic Hepatitis C
by Ozaras, Resat and Salmon-Ceron, Dominique
10/2019, ISBN 9783030037567, 220
Hepatitis C
eBook
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial
by Zeuzem, Stefan and Ghalib, Reem and Reddy, K. Rajender and Pockros, Paul J and Ari, Ziv Ben and Zhao, Yue and Brown, Deborah D and Wan, Shuyan and DiNubile, Mark J and Nguyen, Bach-Yen and Robertson, Michael N and Wahl, Janice and Barr, Eliav and Butterton, Joan R
Annals of Internal Medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Background: Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection. Objective: To evaluate the safety and efficacy... 
SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | SOFOSBUVIR | DOUBLE-BLIND | MK-5172 | SIMEPREVIR | HCV | LABEL PHASE-2 TRIAL | INTERFERON-ALPHA 2A | Quinoxalines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Hepatitis C, Chronic - complications | Viral Load | Young Adult | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Headache - chemically induced | Quinoxalines - therapeutic use | Benzofurans - therapeutic use | Drug Administration Schedule | Administration, Oral | Antiviral Agents - therapeutic use | Liver Cirrhosis - complications | Imidazoles - adverse effects | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Benzofurans - adverse effects | Antiviral Agents - adverse effects | Aged | Antiviral agents | Complications and side effects | Dosage and administration | Research | Drug therapy | Hepatitis C | Liver cirrhosis | Risk factors | Genotype & phenotype | Hepatitis | Protease inhibitors | Medical treatment | Viral infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV a randomized trial
by Sulkowski, Mark S and Sherman, Kenneth E and Dieterich, Douglas T and Bsharat, Mohammad and Mahnke, Lisa and Rockstroh, Jürgen K and Gharakhanian, Shahin and Mccallister, Scott and Henshaw, Joshua and Girard, Pierre-Marie and Adiwijaya, Bambang and Garg, Varun and Rubin, Raymond A and Adda, Mathalie and Soriano, Vincent
Annals of Internal Medicine, ISSN 0003-4819, 07/2013, Volume 159, Issue 2, pp. 86 - 96
Background: Telaprevir (TVR) plus peginterferon-alpha 2a (PEG-IFN-alpha 2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic... 
Vertex pharmaceuticals and janssen pharmaceuticals | MEDICINE, GENERAL & INTERNAL | COINFECTED PATIENTS | MANAGEMENT | RECOMMENDATIONS | PREDICTORS | BOCEPREVIR | HCV | UPDATE | VIROLOGICAL RESPONSE | ASSOCIATION | INTERFERON PLUS RIBAVIRIN | HIV-1 | Recombinant Proteins - therapeutic use | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - pharmacokinetics | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Ribavirin - pharmacokinetics | Interferon-alpha - pharmacokinetics | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Double-Blind Method | Antiviral Agents - therapeutic use | Oligopeptides - pharmacokinetics | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Polyethylene Glycols - pharmacokinetics | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | HIV Infections - complications | Interferon-alpha - adverse effects | Antiviral agents | Patient outcomes | Dosage and administration | Drug therapy, Combination | Research | Hepatitis C | Drug therapy | HIV infection | Drugs | Clinical trials | Hepatitis | Side effects | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text New protease inhibitors for the treatment of chronic hepatitis C: A cost-effectiveness analysis
by Liu, Shan and Cipriano, Lauren E and Holodniy, Mark and Owens, Douglas K and Goldhaber-Fiebert, Jeremy D
Annals of Internal Medicine, ISSN 0003-4819, 2012, Volume 156, Issue 4, pp. 279 - 290
Background: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of... 
UNITED-STATES | ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | US POPULATION | PEGINTERFERON ALPHA-2B | GENOTYPE 1 INFECTION | QUALITY-OF-LIFE | RIBAVIRIN | VIROLOGICAL RESPONSE | HEALTH-STATE UTILITIES | Markov Chains | Ribavirin - economics | Humans | Male | Liver Cirrhosis - economics | Liver Neoplasms - etiology | Interleukins - genetics | Protease Inhibitors - adverse effects | Female | Carcinoma, Hepatocellular - etiology | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Quality-Adjusted Life Years | Liver Cirrhosis - drug therapy | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Risk Factors | Decision Support Techniques | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Genotype | Treatment Outcome | Protease Inhibitors - economics | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Disease Progression | Medication Adherence | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cost-Benefit Analysis | Interferon-alpha - adverse effects | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Research | Protease inhibitors | Hepatitis C | Drug therapy | Health aspects | Clinical trials | Genotype & phenotype | Hepatitis | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Systematic review with meta‐analysis: neuroimaging in hepatitis C chronic infection
by Oriolo, G and Egmond, E and Mariño, Z and Cavero, M and Navines, R and Zamarrenho, L and Solà, R and Pujol, J and Bargallo, N and Forns, X and Martin‐Santos, R
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2018, Volume 47, Issue 9, pp. 1238 - 1252
BackgroundChronic hepatitis C is considered a systemic disease because of extra-hepatic manifestations. Neuroimaging has been employed in hepatitis C... 
INTERFERON-ALPHA | MAGNETIC-RESONANCE-SPECTROSCOPY | VIRUS-INFECTION | MICROGLIAL ACTIVATION | CORTICAL THICKNESS | IN-VIVO | PSYCHIATRIC-DISORDERS | COGNITIVE IMPAIRMENT | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSION | HCV-POSITIVE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | Neuroimaging - methods | Brain - diagnostic imaging | Hepatitis C, Chronic - pathology | Liver Cirrhosis - diagnosis | Magnetic Resonance Spectroscopy | Central Nervous System Viral Diseases - diagnosis | Humans | Brain - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - diagnosis | Central Nervous System Viral Diseases - etiology | Diffusion Tensor Imaging | Brain - metabolism | Magnetic Resonance Imaging | Liver Cirrhosis - virology | Liver Cirrhosis - pathology | Adult | Female | Liver | Nuclear magnetic resonance spectroscopy | Internet/Web search services | Diagnostic imaging | Glutamate | Database searching | Creatine | Online searching | Tomography | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Glutamine | Neuroimaging | Brain | Basal ganglia | Image processing | Emission analysis | Central nervous system | Chronic infection | Spectroscopic analysis | Viruses | Systematic review | Cognition | Mental depression | Magnetic resonance spectroscopy | Confidence intervals | Hepatitis | Alterations | Computed tomography | Encephalopathy | Spectrum analysis | Photon emission | Spectroscopy | Liver diseases | Medical imaging | Abnormalities | Cortex | Positron emission | Fatigue | Patients | Ganglia | Emissions | Neurology | Cirrhosis | Magnetic resonance imaging | Perfusion | Neural networks | Choline | Emissions control | Resonance | Interferon | Positron emission tomography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights